News from immune pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 29, 2015, 16:15 ET

Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has secured financings of up to $21.5 million through two financing...

Jul 17, 2015, 08:00 ET

Immune Pharmaceuticals Joins The Russell Microcap Index

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) today announced that it has joined the Russell Microcap Index at the conclusion of the Russell...

Jul 13, 2015, 08:00 ET

Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP)  announced today that it will participate in the Personalized Medicine: Novel Targeted...

Jul 08, 2015, 08:00 ET

Immune Pharmaceuticals (Immune) Amends Pain Licensing Agreement

 Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a...

Jun 29, 2015, 08:00 ET

Immune Pharmaceuticals Signs License & Research Agreement for AmiKet™ Nano

 Immune Pharmaceuticals Inc. (NASDAQ:IMNP) announced today that it has entered into a definitive license and research agreement with Yissum,...

Jun 25, 2015, 16:30 ET

Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to...

Jun 10, 2015, 08:00 ET

Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine A

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has entered into a binding Memorandum of Understanding with Yissum, the...

May 27, 2015, 16:30 ET

Immune Pharmaceuticals to present at Sachs Immuno-Oncology Business Development (BD&L) and Investment Forum in Chicago and at Marcum Conference in New York

 Immune Pharmaceuticals ("Immune" or the "Company") (NASDAQ: IMNP) will present at the following two conferences this week: Marcum Microcap...

May 18, 2015, 07:30 ET

Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced financial results for the first quarter ended March 31, 2015. Immune filed its...

May 04, 2015, 07:30 ET

Immune Pharmaceuticals and STC Biologics announce strategic partnership to accelerate the development of NanomAbs®

 Immune Pharmaceuticals Inc. (NASDAQ:IMNP), a clinical stage bio-pharmaceutical company with a first-in-class monoclonal antibody,...

Apr 21, 2015, 08:30 ET

Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee

Immune Pharmaceuticals Inc., or "Immune" (NASDAQ: IMNP) announced that its Board of Directors has elected Rene-Pierre Azria as a Director and the...

Apr 15, 2015, 19:00 ET

Immune Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

 Immune Pharmaceuticals Inc., (NASDAQ:IMNP) announced financial results for the fourth quarter and full year ended December 31, 2014. Immune...

Mar 31, 2015, 08:00 ET

Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab

Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced today that it intends to expand its planned bullous pemphigoid (BP)...

Mar 16, 2015, 16:15 ET

Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation of AmiKet

 Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced today that it has entered into a binding memorandum of...

Mar 03, 2015, 07:00 ET

Immune Pharmaceuticals To Present At The Roth Conference

 Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced today that Dr. Daniel Teper, Chief Executive Officer, will be...

Feb 09, 2015, 07:30 ET

Immune Pharmaceuticals Appoints Paul Nadler, MD, EVP, R&D and Chief Medical Officer

 Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced the appointment Dr. Paul Nadler as acting Executive Vice...

Feb 05, 2015, 07:30 ET

Immune Pharmaceuticals To Present At The BIO CEO & Investor Conference

 Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced today that Dr. Daniel Teper, Chief Executive Officer, will be...

Jan 21, 2015, 16:15 ET

Immune Pharmaceuticals Appoints Gad Berdugo as Chief Financial Officer and Dr. Cameron Durrant as Lead Independent Director

Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced today that the Board of Directors has appointed Gad Berdugo as...

Dec 15, 2014, 07:30 ET

Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board.

 Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced today that its Board of Directors has elected Mr. Daniel Kazado...

Dec 01, 2014, 07:30 ET

Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch

 A renowned speaker board, including senior executives from Genzyme, GSK, Takeda, AZ, BMS, Roche, Pfizer, Biogen Idec, among others, and the...